Tesamorelin

Tesamorelin – Long‑Acting GHRH Analog for Visceral Fat and Metabolic Research

Tesamorelin is a 44‑amino‑acid polypeptide analog of human GHRH, engineered with N‑terminal modifications to improve stability and extend its half‑life while selectively activating pituitary GHRH receptors. This targeted secretagogue stimulates endogenous growth hormone release and IGF‑1 production, making it a valuable tool for investigating reductions in visceral adipose tissue (VAT), changes in body composition, and downstream metabolic effects.

Key features

• Visceral‑fat–focused mechanism: Tesamorelin has been shown to significantly reduce VAT in people with HIV‑associated lipodystrophy, with relative preservation of subcutaneous fat and lean mass.

• Endogenous GH/IGF‑1 stimulation: By mimicking native GHRH, tesamorelin promotes physiologic, pulsatile GH secretion and IGF‑1 elevation, allowing researchers to study anabolic and lipolytic effects without exogenous GH.

• Metabolic and cardiovascular markers: Clinical studies report improvements in triglycerides, non‑HDL cholesterol, and insulin‑sensitivity indices alongside VAT reductions, suggesting broader metabolic and cardio‑risk implications.

• Established clinical background: Tesamorelin is one of the few peptides with an FDA‑approved indication for reducing excess abdominal fat in HIV‑associated lipodystrophy, providing robust human safety and efficacy data for researchers to reference.

  
  

Research applications

Tesamorelin is used in experimental and clinical‑adjacent models exploring:

• Visceral adiposity and body‑composition changes, including VAT volume, waist circumference, lean‑mass preservation, and fat‑quality metrics.

• Metabolic syndrome and insulin resistance, assessing effects on glycemic control, lipid panels, inflammatory markers, and cardiovascular‑risk profiles.

• Liver and ectopic‑fat accumulation, particularly nonalcoholic fatty liver disease (NAFLD) and hepatic steatosis in high‑risk populations.

• Aging, cognition, and body‑composition optimization, where GH/IGF‑1–mediated changes in muscle mass, visceral fat, and possibly brain structure and function are of interest.

  
  

Recommended handling

• For controlled laboratory research use only, by qualified professionals.

• Store in a cool, dry environment away from light; follow institutional SOPs for peptide storage, reconstitution, aliquoting, and disposal.

• Investigators should consult current literature and regulatory labels for typical dosing ranges, injection frequency, and imaging/biomarker endpoints relevant to VAT, metabolic health, and GH/IGF‑1 dynamics.

  
  

Important disclaimer

All compounds sold by Rocky Peptide Chain, including Tesamorelin, are for research use only. They are not intended for human consumption, medical use, diagnostic purposes, or treatment of any disease or condition. No claims are made or implied regarding fat loss, muscle gain, anti‑aging, cognitive improvement, or therapeutic benefit. Researchers are solely responsible for appropriate handling, experimental design, and compliance with all applicable regulations.